Phase IIa trial of CX 1739 in patients with central sleep apnoea

Trial Profile

Phase IIa trial of CX 1739 in patients with central sleep apnoea

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2016

At a glance

  • Drugs CX 1739 (Primary)
  • Indications Sleep apnoea syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jan 2016 The company will present an update about this trial at the Biotech Showcase 2016, according to a RespireRx Pharmaceuticals media release.
    • 01 May 2015 This trial will be discussed at the NewYorkBIO 25th Anniversary Conference in May 2015, according to a Cortex Pharmaceuticals media release.
    • 08 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top